Hilliary Van Voorhies

Hilliary Van Voorhies joined Flagship in 2024 as Director of Program and Alliance Management, on the Pioneering Medicines Portfolio Strategy and Operations team. She brings 15 years of drug discovery experience in start-up and mid-size organizations to her role and is responsible for developing and managing strategic partnerships and projects with novel modalities between Pioneering Medicines, Flagship platform companies, and external partners.

Over her career Hilliary has led several small- and large-molecule program teams from the exploratory phase through IND-enabling and has a passion for organization, problem-solving, and creating efficiencies. She joined Flagship from Arkuda Therapeutics where she served as Director of R&D Program Management leading their frontotemporal dementia program through the IND-enabling phase. She began her career as a drug metabolism and pharmacokinetics (DMPK) scientist at Forum Pharmaceuticals responsible for managing the pharmacokinetics team and conducting in vivo experiments to develop treatments for neurodegenerative disease. Hilliary transitioned to program management in 2016 and joined Alkermes, leading the preclinical program management team and managing CNS and oncology drug discovery projects.

Hilliary earned her B.S. in Animal Science from the University of Massachusetts-Amherst, and continued her graduate work there, earning a M.S. in Animal Biotechnology and Biomedical Sciences.